Nabendu Pore

Nabendu Pore, PhD, currently serves in Global Clinical Development for Early Oncology at AstraZeneca as of 2024. Previously, Nabendu led cross-functional matrix teams at BeiGene, from July 2021 to November 2023, overseeing multiple compounds in various development stages, including TIM3, PD/L-1, and novel biologics. From February 2015 to June 2021, Nabendu was a Global Development Lead & Clinical Scientist at AstraZeneca, focusing on ADCs, IOs, and SM, contributing to projects from target identification to Phase II. Initial roles included positions at MedImmune, the University of Pennsylvania, and the National Cancer Institute. Academic credentials include a Post Doctoral Fellowship in Cancer Biology from the University of Pennsylvania, a PhD in Cellular and Molecular Biology from Jadavpur University, and an MSc in Biophysics and Molecular Biology from the University of Calcutta.